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Background: Chronic airway diseases are often asso-
ciated with marked mucus production, however, little
is known about the regulation of secretory activity by
locally released endogenous mediators.
Aim: This investigation was performed to determine
the release of MUC5AC mucin from human bronchial
preparations using the purinergic agonists adenosine
59-triphosphate  (ATP)  and  uridine  59-triphosphate
(UTP).
Methods:  Immunohistochemical  and  immunoradio-
metric assays (IRMA) were used to detect the MUC5AC
mucin.  Immunohistochemical  analysis  were  per-
formed  using  individual  1–13  M1  and  21  M1  MAbs
recognizing a recombinant M1 mucin partially enco-
ded by the MUC5AC gene. IRMA measurments were
performed  using  a  mixture  of  eight  anti-M1  mucin
MAbs (PM8), which included both 1–13 M1 and 21 M1
MAbs. Lysozyme and protein were also measured in
the biological fluids derived from human bronchial
preparations obtained from patients who had under-
gone surgery for lung carcinoma.
Results: The anti-M1 monoclonal antibodies labelled
epithelial  goblet  cells.  After  challenge  of  human
bronchial  preparations  with  ATP,  the  goblet  cells
exhibited less staining. In contrast, UTP did not alter
the immunolabelling of goblet cells. MUC5AC mucin in
the  bronchial  fluids  derived  from  ATP-challenged
preparations was increased while UTP had no effect on
release.  ATP  did  not  alter  either  the  quantities  of
lysozyme or protein detected in the biological fluids.
Conclusion: These results suggest that ATP may reg-
ulate  epithelial  goblet  cell  secretion  of  MUC5AC
mucin from human airways in vitro.
Key  words: ATP;  M1/MUC5AC  mucins;  Human  airways;
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Introduction
Experimental  models  have  shown  that  secretory
activity  in  respiratory  tissues  may  be  regulated  by
neutrophil elastase1, inflammatory mediators such as
tumor necrosis factor-a2,  platelet-activating factor2,3
and purinergic agonists such as ATP and UTP.5–6 In
these reports  the release of  mucins  from  epithelial
cells  was  monitored  either  by  immunoassays  with
various  antibodies2,3,7,  incorporation  of  radiolabels
such as  3H-glucosamine into secretory cells6,8–10 or
videomicroscopy by measuring the degranulation rate
of  goblet  cells  after  stimulation  with  purinergic
agonists.4,5Although these studies provided informa-
tion on the effects of agonists on secretory activity,
the specific subclass of mucins released subsequent
to cell stimulation has not been clearly established.
Recently, Labat and coworkers11 studied the secre-
tion of MUC5AC mucin  from human airway tissues
and demonstrated that human bronchial ring prepara-
tions  challenged  with  a  variety  of  agents  failed  to
release  the  MUC5AC  mucin  from  epithelial  goblet
cells.  These  results  suggested  that  the  release  of
mucins from human goblet cells may be regulated by
another mechanism.
Since  purinergic  agonists  have  been  reported to
cause  degranulation  of  goblet  cells  and  induce  the
release of glycoproteins, the aim of this study was to
evaluate the effects of ATP and UTP on the release of
MUC5AC mucin from human bronchial preparations
using both immunohistochemical and immunoradio-
metric  assays  (IRMA).  This  investigation  was  per-
formed to examine whether or not specific mucins
were liberated when goblet cells of human airways
were activated by these agonists.
Materials and methods
Tissues
Human lung tissues were obtained from 14 patients
who  had  undergone  surgery  for  lung  carcinoma.
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distance  from  the  tumor  area.  Subsequently,  the
bronchi  (first  to  third  generation  bronchi)  were
dissected  free  from  the  parenchyma  tissue  and
washed with Tyrode’s solution, pH 7.4 as previously
described by  Soss´ e-Alaoui.12 Bronchial tissues  were
cut  as  rings  of  constant  length  and  wet  weight
(4–7mm  internal  diameter  and  100–500mg  wet
weight). A  total  of  26  bronchial  preparations were
examined.
M1 mucin standard and monoclonal antibodies
M1  mucins  isolated from an ovarian mucinous cyst
fluid were used as standard. Eight MAbs raised against
epitopes  associated  with  the  peptide  core  of  M1
mucins allowed the detection of mucins.13These anti-
M1  mucin  MAbs  are  IgG1.  Immunohistochemical
analysis  were  performed  using  individual  1–13  M1
and  21  M1  MAbs  recognizing  a  recombinant  M1
mucin  partially  encoded  by  the  MUC5AC gene.14
IRMA experiments were performed using a mixture
of eight anti-M1 mucin MAbs (PM8), which included
both 1–13 M1 and 21 M1 MAbs.
Immunohistochemical analysis
Control  tissues  and  preparations  challenged  with
extracellular ATP and UTP (0.1mM; Sigma Chemical
Co., St Louis)  were fixed  in  formalin for 12 hours,
dehydrated,  embedded  in  paraffin  and  sections  of
tissues (5mm) were cut. Tissue sections were depar-
affinized with toluene, rehydrated with a gradient of
ethanol  and  rinsed  in  phosphate  buffered  saline
(PBS)  10mM,  pH  7.4  containing  0.1%  Tween  20.
Sections  were  then treated with  0.025%  pronase E
(Calbiochem,  France)  in  0.05M Tris-HCl  buffer,  pH
7.6  for  7min  at  room  temperature  to  unmask  the
mucin epitopes.15After several washes of sections in
PBS-0.1% Tween  20,  endogenous  peroxidases  were
eliminated  with  3%  H2O2 in  methanol  for  5min.
Tissues  sections  were  then  incubated  in  PBS-0.1%
Tween 20 containing 1% BSA (Sigma Chemical Co.,
St  Louis)  for  5  minutes  at  room  temperature  and
incubated with the individual  1–13  M1  and 21  M1
MAbs at the final concentration of 10mg/ml in PBS-
1%  bovine  serum  albumin  (BSA)  for  1  hour.  A
negative  control was also  performed by  incubating
bronchial rings sections with PBS-1% BSA for 1 hour.
After  several  washes  with  PBS-0.1% Tween  20,  tis-
sues sections were incubated with horseradish per-
oxidase conjugated anti-mouse IgG (Sigma Chemical
Co.,  St  Louis)  diluted  in  PBS  for  1  hour  at  room
temperature. The  peroxidase  activity  was  revealed
using  the diaminobenzidine/H2O2 revelation system
as  described  in  the  LSAB-2  kit  (Dako  Laboratories,
USA) for 10 minutes in darkness and tissues sections
were counter-stained with Harris hematoxylin.
Periodic acid Schiff (PAS) staining
Tissue sections (5mm) from control tissues and ATP-
challenged  bronchial  preparations  were  deparaffi-
nized  and  rehydrated  as  described  above.  Sections
were  then  treated  with  0.5%  periodic  acid  for  10
minutes, washed in distilled water and stained with
Schiff  reagent  (Surgipath,  UK)  for  30  minutes  at
room  temperature. After several washes  in  distilled
water,  sections  were  counter-stained  with  Harris
hematoxylin.
Functional studies
The  human  bronchial  preparations  were  placed  in
separate wells of a 24-well plate (Costar, UK) contain-
ing  1ml  of Tyrode’s solution and equilibrated for 1
hour at 37°C in a humidified incubator (5% CO2/air).
At the end of this equilibration period, the medium
was exchanged and fresh Tyrode’s solution previously
warmed  at  37°C  was  added.  After  1  hour  the
bronchial  fluids  containing  the  human  secretory
mucins (Period I; basal release) were collected. Fresh
medium (Tyrode’s solution) was added for 30 minutes
to the bronchial preparations. After this period of pre-
treatment,  the  medium  was  again  removed  and
bronchial  rings  were  placed  in  Tyrode’s  solution
containing either ATP (0.1mM) or UTP (0.1mM) for 1
hour. In some preparations, a short time-course study
was performed by stimulating the bronchial prepara-
tions with ATP (0.1mM) or UTP (0.1mM) in Tyrode’s
solution for 10, 20, 30, 40 and 60 seconds. At each
time, bronchial fluids were collected and stored. In
another series of experiments, the effects of ATP and
UTP were examined in preparations stimulated for 5,
30  and  60  minutes  with  these  agents  (Period  II;
stimulation). The bronchial fluids  were collected at
each Period and stored at –20°C.
Immunoradiometric assay (IRMA)
A  solid-phase  double-antibody-sandwich  immunor-
adiometric  assay  (IRMA)  was  used  as  previously
described.16 Polystyrene  stars  (Oris  Industrie,  Saint
Quentin en Yvelines, France) were coated with the
1–13 M1 MAb (10mg/ml in 0.01M PBS, pH 7.4) by
incubating overnight at 37°C, rinsed three times with
PBS-0.1% Tween  20  and  subsequently  incubated  in
PBS-1% BSA overnight at 37°C. After several washings,
stars were dried at 40°C and stored at 4°C until used.
The M1 mucin standard (10mg/ml), as well as human
bronchial  fluids  were  serially  diluted  in  PBS-0.1%
Tween 20. A volume of 300ml of each dilution was
added to the 1–13 M1 MAb coated-stars and incubated
overnight at 37°C. Stars were then washed with PBS-
0.1%  Tween  20  and  incubated  with  PM8  MAbs
previously radiolabelled with  125I (5 ´ 105 cpm/ml)
overnight  at  37°C.  Subsequently,  the  stars  were
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scintillation  counter  (Wizard  Model  147  005). The
concentration  of  mucin  contained  in  the  human
bronchial fluids was estimated from the IRMA stand-
ard  curve  obtained  with  the  M1  mucin  standard.
Mucin concentrations were determined in bronchial
fluids  derived  from  14  lungs  (controls  and  ATP-
challenged bronchial preparations) and 6 lungs (UTP-
challenged preparations).
Protein determination
Determination of total protein was performed system-
atically  on  an  aliquot  (100ml)  taken  from  human
bronchial fluids collected from control and stimulated
bronchial preparations. Total proteins were measured
using the Lowry procedure17 with BSA as standard.
Assay of lysozyme
Lysozyme was assayed by measuring the rate of lysis of
a  suspension  of  Micrococcus  lysodeikticus (Sigma
Chemical Co., St Louis).18 A stock suspension of M.
lysodeikticus of  3mg/ml  was  prepared.  Bronchial
fluids  collected  from  control  and  ATP-challenged
bronchial tissues were diluted in distilled and deio-
nized water (1:4 v/v) and acetic acid was added to
adjust the pH  to 4.5.  Samples were then heated at
100°C  for  2min  to  precipitate  impurities.19,20 An
aliquot of 200ml of each treated bronchial fluid was
added to 1.8ml of 50mM potassium phosphate buffer,
pH  7.4  containing  M.  lysodeikticus  (300mg/ml),
sodium azide (1mg/ml), BSA (1mg/ml) and incubated
at 37°C for 2 hours. Standard curves were constructed
by  incubating  egg-white  lysozyme  (Sigma  Chemical
Co.,  St  Louis)  (0.5  to  100ng/ml)  in  1.5ml  of
50mM potassium phosphate buffer, pH 7.4 containing
M. lysodeikticus, sodium azide, BSA and incubated at
37°C for 2 hours. After incubation, the optical densities
were  measured  at  a  wavelength  of  450nm  with
potassium phosphate, pH 7.4 containing BSA as blank.
The lysozyme concentration in each human bronchial
fluid was estimated from the standard curve.
Calculation
The concentration of MUC5AC mucin detected in the
fluids derived from human bronchial preparations by
the IRMA are expressed asmg of MUC5AC mucin/ml
and  were  estimated  from  the  M1  standard  curves.
Lysozyme concentrations were expressed asng/ml. All
results  are  means  ±  SEM.  Statistical  analysis  were
performed using the Student’s t-test. A value (P<0.05)
was taken as an indication of significance.
Results
Immunohistochemistry
MUC5AC  mucin  in  the  intracellular  organelles  of
epithelial goblet cells of unstimulated bronchial pre-
parations were labeled with the 1–13 M1 MAb (Fig.
1B) and 21 M1 MAb (Fig. 1C) when compared with
the unlabeled control (Fig. 1A). In addition, MUC5AC
mucin  were observed on the surface epithelium  in
contact with cilia of ciliated cells (Fig. 1).
Subsequent to a 60-min ATP (0.1mM) challenge of
human  bronchial preparations,  less labelling  of  the
MUC5AC  mucin  was  observed  in  the  intacellular
organelles of goblet cells with the 1–13 M1 MAb (Fig.
2A)  and  21  M1  MAb  (Fig.  2B).  Most  goblet  cells
exhibited weak labelling or were devoid of mucins.
However,  MUC5AC  mucin  was  detected  with  the
1–13 M1 and 21 M1 MAbs (Fig. 2A, 2B) in some goblet
ATP and mucin release
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FIG. 1. Immunohistochemical staining of isolated human bronchial preparations with anti-M1 MAbs. No labelling of epithelial
goblet cells was observed in the negative control (A). In unstimulated bronchial tissues, goblet cells in the surface epithelium
were intensely labelled with the 1–13 M1 MAb (B) and the 21 M1 MAb (C). Internal scale bar = 80mm.P. Roger et al.
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FIG. 2. Immunohistochemical staining of human bronchial preparations with anti-M1 MAbs after stimulation with either ATP
(0.1mM; panels A and B) or UTP (0.1mM, panels C and D). In ATP-challenged bronchial preparations, intracellular organelles
of the epithelial goblet cells were weakly labelled with the 1–13 M1 MAb (A) and 21 M1 MAb (B). Some epithelial goblet cells
were devoid of MUC5AC mucin (arrow). In contrast, in bronchial preparations challenged with UTP, MUC5AC mucin in the
intracellular organelles of epithelial goblet cells were intensely labelled with the 1–13 M1 MAb (C) and the 21 M1 MAb (D).
Internal scale bar = 80mm.
FIG. 3. Detection of MUC5AC mucin released from human bronchial preparations in vitro using an immunoradiometric assay
and pooled anti-M1 MAbs (PM8). Data are presented as means ± SEM and are from Period I (unstimulated tissues; 14 human
lungs) and after stimulation with the different agonists (Period II). The effects of ATP (0.1mM; 14 human lungs) and UTP
(0.1mM; 6 human lungs) were analyzed after 5, 30 and 60min of stimulation of bronchial preparations.
*** indicates a significant difference (P<0.001) from paired time control bronchial preparations.cells.  In  bronchial  tissues  stimulated  with  UTP
(0.1mM),  the  intracellular  organelles  of  epithelial
goblet  cells  exhibited  the  same  labelling  with  the
1–13 M1 and 21 M1 MAbs (Fig. 2C, 2D) as observed in
unstimulated bronchial preparations (Fig. 1B, 1C).
MUC5AC mucin release from human bronchial
rings: effects of ATP and UTP
The basal release of MUC5AC mucin from unstimu-
lated  human  bronchial  preparations  was:  0.80  ±
0.15mg/ml (Period I, 21 bronchial preparations from
14  lungs;  Fig.  3). This  value  was  not  significantly
altered during the experimental protocol under con-
trol conditions (Period II). When bronchial prepara-
tions  were  stimulated with  either ATP  (0.1mM)  or
UTP (0.1mM) at 10 second intervals from 10 to 60
seconds,  no  detectable  release  of  MUC5AC  mucin
from  bronchial  tissues  was  observed (21  bronchial
preparations from one lung; data not shown). How-
ever,  a  significant  increase  in  the  MUC5AC  mucin
concentrations measured in bronchial fluids derived
from  human  preparations was observed after 5, 30
and 60 minutes challenge with ATP (0.1mM) when
compared with paired control preparations from the
same human lungs (Fig. 3). In contrast, no significant
increase in the MUC5AC mucin release from goblet
cells was detected when bronchial preparations were
stimulated with UTP (0.1mM).
Protein release from human bronchial
preparations
A significant  decrease in the concentration of  total
proteins measured in bronchial fluids  derived from
human preparations was observed during the experi-
mental  protocol (Period  I  versus  Period II;  Fig.  4).
However  subsequent  to  a  5min,  30min  or  60min
challenge  of  human  bronchial  preparations  with
either ATP (0.1mM) or UTP (0.1mM), no significant
difference  in  the  protein  concentrations  was
observed when results from ATP or UTP-challenged
bronchial preparations were compared with control
preparations at each time interval (Period II; Fig. 4).
ATP and mucin release
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FIG. 4. Protein was determined in fluids derived from unstimulated bronchial preparations and tissues challenged with ATP
(0.1mM) and UTP (0.1mM). Data are presented as means ± SEM and are from Period I (unstimulated tissues; 6 human lungs)
and after stimulation for 5, 30 and 60min (Period II) with ATP (0.1mM; 6 human lungs) and UTP (0.1mM; 6 human lungs).
*** indicates a significant difference (P<0.001) from basal values (Period I).
FIG.  5.  Lysozyme was  determined in  the  bronchial  fluids
derived from  human preparations obtained at  Period  I  (3
human  lungs)  and  after  a  60  min-challenge  with  ATP
(0.1mM; Period II; 8 human lungs). Values obtained from ATP
challenged-tissues (open bar)  were  compared with  paired
controls (solid bar). Values are means ± SEM for control and
ATP-treated bronchial tissues.Effect of ATP on lysozyme and mucin release
from bronchial submucosal glands
Stimulation  of  human  bronchial  preparations  with
ATP (0.1mM) for 60 minutes had no significant effect
either on lysozyme release from bronchial tissues (Fig.
5) or on the release of mucins from glandular cells as
demonstrated  by  the  intense  PAS-staining  of  the
submucosal  glands  in ATP-challenged  bronchial  tis-
sues  (0.1mM;  Fig.  6B).  However,  while  epithelial
goblet cells and glands exhibited a strong PAS-staining
in  unstimulated  tissues  (Fig.  6A),  few  PAS-positive
epithelial goblet cells were observed after ATP chal-
lenge of bronchial preparations (Fig. 6B).
Discussion
This  study  provides  evidence  that  MUC5AC  mucin
was  detected  in  goblet  cells  of  the  surface  epithe-
lium of human airways. ATP reduced the immunohis-
tochemical  labelling  of  epithelial  goblet  cells  and
was associated with a significant increased accumu-
lation  of  MUC5AC  mucin  in  the  bronchial  fluids
derived from  human  tissues. The quantities  of  pro-
tein  and  lysozyme  detected  in  the  fluids  derived
from  ATP-challenged  bronchial  preparations  were
not significantly altered compared with unstimulated
preparations. In addition, while  the PAS staining of
the submucosal glands was not altered in bronchial
P. Roger et al.
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FIG. 6. PAS-staining of unstimulated human bronchial preparations (panel A) and tissues challenged with ATP for 60min (panel
B). An intense staining of mucins was observed in the lumen of the submucosal glands (GL) of the unstimulated and ATP-
challenged bronchial preparations (A, B). While epithelial goblet cells of unstimulated tissues were PAS-positive (A), goblet
cells of the surface epithelium (EP) of ATP-challenged tissues were not stained (B). Internal scale bar = 160mm.tissues  stimulated  with ATP,  a  reduced  staining  of
mucins  was  observed  in  the  goblet  cells  of  the
airway surface epithelium. Challenge of human bron-
chial  preparations  with  UTP  did  not  modify  the
release  of  either  MUC5AC  mucin  or  protein  from
human bronchial preparations. These results suggest
that ATP challenge of human bronchial preparations
may  be  associated  with  the  release  of  MUC5AC
mucin  from  human  bronchial  epithelial  goblet
cells.
Several  mucin  genes  have  been  identified  in  the
human  respiratory  tract.  MUC1,  MUC2,  MUC3  and
MUC5AC mRNAs were detected in the surface epi-
thelium  and  MUC4,  MUC5B,  MUC5AC,  MUC8
mRNAs were present in the submucosal glands.21–24
Of these, MUC5AC and MUC5B were the only mucin
gene  products  isolated from  normal  human  airway
secretions.25,26 The  MAbs  used  (present  report)
labelled  goblet  cells  of  the  bronchial  epithelium11,
cells which are known to express predominantly the
MUC5AC mucin gene.22
Although  MUC5AC  mucin  was  detected  in  the
intracellular  organelles  of  epithelial  goblet  cells  of
unstimulated  and  UTP-challenged  bronchial  tissues,
less  labelling  was  observed  in  preparations  chal-
lenged  for  60min  with  extracellular  ATP  (0.1mM;
present report). Previous data4–6 clearly showed that
isolated airway epithelial goblet cells were activated
by  extracellular  ATP  (0.1mM)  and  that  the  goblet
cell  degranulation  was  extremely  rapid  since  this
phenomenon  reached  a  plateau  within  5  minutes
after challenge of isolated goblet cells and within 10
minutes after challenge of airway explants with ATP.4
While there is evidence that ATP is rapidly metabo-
lized27 to ADP and adenosine, these metabolites do
not  appear  to  alter  either  cAMP  levels28 or  mucin
secretion5,9,  suggesting  that  ATP  is  the  principal
neurotransmitter  involved  in  the  secretory  activity.
In  addition,  the  rapid  degranulation  of  epithelial
goblet  cells  observed in  lung  explants4,  pancreatic
epithelial cells29 and the significant increase in  the
release of MUC5AC mucin after a 5 minute challenge
of bronchial preparations with ATP (present report)
support  the  notion  that  ATP  provoked  a  rapid
release of MUC5AC mucin from human  airway epi-
thelial  goblet  cells. These data (present study)  sup-
port the observations of Shin et al.,30 who demon-
strated  that  ATP  caused  mucin  release  from  rat
airways in vivo. Furthermore, a low basal degranula-
tion  rate  in  human  bronchial  explants  which  was
similar  to  that  reported  in  canine  goblet  cells  has
been  reported.4 The  data  (present  report)  confirm
this observation since there was a low and constant
level  of  MUC5AC  mucin  detected  in  the  medium
surrounding the unstimulated human bronchial pre-
parations,  suggesting  a  continuous  release  of
MUC5AC  mucin.  The  results  (present  report)  also
demonstrated  a  preferential  activity  of  ATP  at  the
epithelial layer since few  secretory granules  of  epi-
thelial goblet cells were positive after ATP challenge
when compared with unstimulated preparations. In
contrast, there was always a comparable PAS staining
of the bronchial submucosal glands in untreated and
stimulated tissues.
The  detection  of  lysozyme  has  frequently  been
used  as  an  index  of  the  secretory  activity  of  sub-
mucosal glands in tissues derived from the respiratory
tract of several species18 including  man.23,31 In the
present study,  extracellular ATP did not modify  the
release of lysozyme from the submucosal gland cells
since the levels detected in the fluids obtained from
bronchial tissues challenged with this agent were not
significantly different from controls.
The inflammatory response in the human respira-
tory tract has often been associated with increased
mucus  production. The  data  derived  from  human
airways (present report) suggest that a perturbation at
the  neuronal  level  may  also  be  involved  in  the
increased  levels  of  sputum  which  are  frequently
observed  in  patients  with  airway  diseases.  While
further  work  is  needed  to  identify  the  receptors
involved, the present data extend the initial observa-
tions  that  extracellular ATP,  in  addition  to  evoking
degranulation of goblet cells4 also induced the release
of  MUC5AC  mucin  from  human  bronchial  prepara-
tions. These results suggest that purinergic agonists
may play a role in the release of gene products from
human goblet cells.
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